Phase 2 N=49 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Metastatic Cancer · Sarcoma
Primary: Status of FAS Ligand in Pre-chemotherapy Sample — 7; 5; 1; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
Endometriosis
Primary: Bone Mineral Density — 0.01; -0.11 g/cm^2 — p=0.10
Phase 4 N=26 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Retinoblastoma
Primary: Event Free Survival Rate — 7; 4 participants — p=0.034
Phase 2 N=32 Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: Percentage of Parts 2 and 3 Participants Who Achieved American College of Rheumatology Response of 20 (ACR20) — 46; 27 percentage of participants
Phase 1 N=12 A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0 Participants
Phase 2 N=116 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Adult Rhabdomyosarcoma · Adult Synovial Sarcoma · Childhood Hepatoblastoma
Primary: Disease Response — 10; 10; 19; 10 patient
Phase 3 N=151 Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.
Infertility
Primary: Total Number of Oocytes Retrieved — 10.9; 12.0 oocytes
Phase 2 N=11 Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Leukemia, Myelomonocytic, Acute
Primary: Overall Response Rate (Defined as Partial Remission or Better) to 3 Months of Treatment With Erlotinib — 0 percentage of participants
N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
Phase 2 N=55 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Relapsed and Bortezomib Refractory Multiple Myeloma · Refractory Multiple Myeloma · Multiple Myeloma in Relapse
Primary: Overall Response Rate (PR+nCR+CR) — 34.5 percentage of participants
Phase 3 N=870 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12) — 98.6; 97.2; 98.2; 99.1 percentage of…
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
Phase 1 N=6 ADSC Injections for Pain Management of Osteoarthritis in the Human Knee Joint
Osteoarthritis of the Knee
Primary: Safety as Measured by Adverse Events — 0 percentage of participants
Phase 2 N=404 AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
Chronic Plaque-type Psoriasis
Primary: The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque-type Psoriasis With Respect to PASI 75…
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05